Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 3:7:100164.
doi: 10.1016/j.rcsop.2022.100164. eCollection 2022 Sep.

A protocol for a randomized controlled trial comparing Sleepwell, EMPOWER, and treatment-as-usual for benzodiazepine receptor agonist discontinuation in older adults: the your answers when needing sleep in New Brunswick (YAWNS NB) study

Andrea L Murphy  1   2 , Justin P Turner  3   4   5 , Malgorzata Rajda  1   6   7 , Sandra Magalhaes  8 , Kathleen G Allen  1 , David M Gardner  1   2
Affiliations

A protocol for a randomized controlled trial comparing Sleepwell, EMPOWER, and treatment-as-usual for benzodiazepine receptor agonist discontinuation in older adults: the your answers when needing sleep in New Brunswick (YAWNS NB) study

Andrea L Murphy et al. Explor Res Clin Soc Pharm. .

Abstract

Background: Chronic benzodiazepine receptor agonist (BZRA) use among older adults is a public health concern given cognitive and physical risks. One in four older adults in New Brunswick, Canada, is a long-term user of BZRAs. Previous studies using a direct-to-patient approach as the primary intervention target have shown promise in reducing BZRA use. The Your Answers When Needing Sleep in New Brunswick (YAWNS NB) study aims to reduce the long-term use of BZRAs in older adults and increase the use of cognitive behavioural therapy for insomnia (CBTi), which is the recommended first line treatment.

Methods: The trial (ClinicalTrials.gov registration NCT04406103) is a three arm, open-label, parallel randomized controlled trial in NB, Canada. Eligible participants 65 years and older using BZRAs long-term will be randomly allocated to: the Eliminating Medications through Patient Ownership of End Results (EMPOWER) information package group; the Sleepwell information package group; or treatment-as-usual (TAU). Information packages will be mailed via Canada Post. The primary outcome of BZRA discontinuation at 6 months will be compared across groups. Secondary outcomes include participants with ≥25% BZRA dose reduction, and switching to newly prescribed alternate sedative-hypnotics. Several exploratory outcomes will also be examined.

Discussion: Targeting participants with information packages informing them of appropriate use, dangers, and approaches to reducing BZRA use and increasing CBTi use may be beneficial in a region of Canada with the highest rate of chronic BZRA use in older adults. Comparing information packages and TAU will provide insights into the effectiveness of direct-to-patient interventions for BZRA reduction.

Keywords: Benzodiazepine receptor agonists (BZRAs); Benzodiazepines; Chronic insomnia; Cognitive-behavioural therapy for insomnia (CBTi); EMPOWER; Sedative-hypnotic; Sleepwell; Z-drugs.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram for the YAWNS NB study.
See this image and copyright information in PMC

References

    1. Government of Canada SC Population Estimates, Quarterly. 2022. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000901 Published December 16, 2021. Accessed April 25.
    1. Canadian Institute for Health Information The Use of Selected Psychotropic Drugs Among Seniors on Public Drug Programs in Canada, 2001 to 2010. 2022. https://secure.cihi.ca/free_products/psychotropic_AIB_2012_en.pdf Published online March 2012. Accessed April 25.
    1. Canadian Institute for Health Information Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to 2017. 2022. https://www.cihi.ca/sites/default/files/document/opioid-prescribing-june... Published online 2018. Accessed April 25.
    1. Canadian Deprescribing Network 2017 Annual Report. 2022. https://www.deprescribingnetwork.ca/reports Accessed April 25, 2022.
    1. Canadian Institute of Health Information . 2018. Drug Use among Seniors in Canada, 2016; pp. 1–63.www.cihi.ca

Associated data